+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

You are here : Home / 2025 / March

New hands-on material characterization seminar by NANBIOSIS experts and NANE

Technical Seminar on Materials Characterization by NANBIOSIS Unit 6 & NANE on April 1, 2025, at ICMAB-CSIC. Hands-on training & latest techniques. Register now!

Barcelona, march 2025. The Soft Materials Lab – NANBIOSIS Unit 6, in collaboration with NANE, is pleased to invite researchers, professionals, and students to a Technical Seminar on Materials Characterization. The event will take place on Tuesday, April 1st, 2025, from 9:30 AM to 5:00 PM at the Institute of Materials Science of Barcelona (ICMAB-CSIC).

This seminar will provide attendees with an opportunity to explore the latest advancements in particle size analysis techniques and gain hands-on experience with state-of-the-art equipment. Participants will be introduced to techniques such as laser diffraction analysis, dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), and other advanced characterization methods.

Seminar Structure

  • Theoretical session: Overview of fundamental principles and recent developments in materials characterization.
  • Practical session: Hands-on experience with cutting-edge equipment and analytical techniques.

Attendees who require proof of participation can request a certificate of attendance from the organizing company.

Registration and Contact Information

Interested participants can register [here] to attend this seminar.

For more information, you can contact NANE at:

Alternatively, you may reach out to Amable Bernabé (Soft Materials Lab – NANBIOSIS UNIT 6) at jabernabe@icmab.es.

This seminar is a valuable opportunity to enhance your knowledge and practical skills in materials characterization. We look forward to your participation!

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

New breakthrough in preventing infections in biomedical implants

A new TPU surface modification with an antimicrobial protein prevents biofilm formation in implants, offering an alternative to antibiotics and metal coatings.

Barcelona, february 2025. Infections associated with medical implants are a serious health issue. A new study presents a chemical modification of thermoplastic polyurethane (TPU) with an antimicrobial protein that reduces the formation of biofilms of multidrug-resistant bacteria, offering an alternative to antibiotics and metal coatings in these devices.

A team of researchers has developed a new strategy to chemically modify TPU, a material widely used in medical devices, to endow it with antibacterial properties and prevent infections associated with biomedical implants. This innovation could represent a significant advancement in the safety and durability of medical implants. The study is part of a project funded by La Marató de TV3.

The study, led by Imma Ratera, researcher at the Nanomol-Bio group at ICMAB-CSIC and CIBER-BBN, and recently published in ACS Applied Bio Materials, describes how the chemical modification of the TPU surface and the self-assembled monolayer strategy are key to enabling the anchoring of the recombinant human α-defensin 5 (HD5) protein.

This specific surface functionalization promotes interaction with the antimicrobial protein, effectively inhibiting bacterial biofilm formation. The surface modification was achieved through a three-step process: activation of TPU with hexamethylene diisocyanate (HDI), interfacial reaction with polyethylene glycol (PEG) derivatives, and finally, a simple click reaction between the PEG-maleimide terminated assembled monolayer and the HD5 protein.

The material has been characterized using advanced surface science techniques, confirming its antibacterial efficacy. The results show a significant reduction in the formation of biofilms of resistant gram-positive and gram-negative bacteria, such as Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA), and methicillin-resistant Staphylococcus epidermidis (MRSE).

This technology offers a promising alternative to antibiotics and metals like silver, addressing the issue of antimicrobial resistance in implantable medical devices. “This breakthrough could represent a paradigm shift in preventing infections in medical implants, reducing complications, and improving patient safety,” says Ratera.

This discovery opens new avenues for the development of antimicrobial surfaces in medical devices, with great potential to improve clinical outcomes and reduce healthcare costs associated with hospital-acquired infections.

The study was conducted by researchers from the Institute of Materials Science of Barcelona (ICMAB-CSIC) and the Biomedical Research Networking Center – Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), in collaboration with the Institute of Agrifood Research and Technology (IRTA), the Hospital Clínic-Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) with the Biomedical Research Networking Center on Infectious Diseases (CIBER-INFEC), and the Hospital Universitari Parc Taulí.

The luminescence characterization of the modified TPU surfaces was carried out at Unit 6 of the ICTS Nanbiosis, specializing in the preparation and characterization of nanostructured biomaterials.

For more information, you can consult the full article in ACS Applied Bio Materials.

Reference article:

Activating Thermoplastic Polyurethane Surfaces with Poly(ethylene glycol)-Based Recombinant Human α-Defensin 5 Monolayers for Antibiofilm Activity
Xavier Rodríguez Rodríguez, Adrià López-Cano, Karla Mayolo-Deloisa, Oscar Q. Pich, Paula Bierge, Nora Ventosa, Cristina García-de-la-Maria, José M. Miró, Oriol Gasch, Jaume Veciana, Judith Guasch, Anna Arís, Elena Garcia-Fruitós, Imma Ratera, the FUNCATH investigators
ACS Applied Bio Materials, 20 Feb 2025
DOI: 10.1021/acsabm.4c00732

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Online Seminar: Microphysiological Systems for Cell Biology and Cancer Immunology

Online seminar on April 2 at 15:00h CET with Dr. Jose Maria Ayuso on microphysiological systems for cell biology and cancer immunology. Join via Zoom!

Zaragoza, March 2025. The CIBER group CB06/01/0069, where our Unit 13 is located, is organizing an online seminar featuring Dr. Jose Maria Ayuso from the University of Wisconsin-Madison. The talk, titled “Microphysiological systems for cell biology and cancer immunology”, will take place on April 2, 2025, at 15:00h (CET).

Dr. Ayuso’s research focuses on the development of microphysiological systems to study complex biological processes, particularly in the context of cancer immunology. His work aims to bridge the gap between in vitro models and clinical applications, providing innovative solutions for biomedical research.

The event will be held via Zoom, and all interested participants can join through the following link: https://us02web.zoom.us/j/85843455383.

This seminar represents a valuable opportunity for researchers, students, and professionals in the field of nanomedicine, bioengineering, and cancer research to gain insights from a leading expert in the field.

Stay connected with NANBIOSIS for more updates on upcoming scientific events!

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Hamill Industries visits NANBIOSIS during new artistic residency

Hamill Industries visited NANBIOSIS Unit 7 at IBEC, merging art and nanotech through the Ciència Radical program to inspire new audiovisual creations.

Barcelona, march 2025. Last week, the Institute for Bioengineering of Catalonia (IBEC) had the pleasure of welcoming the renowned visual artist collective, Hamill Industries, as part of the Ciència Radical artistic residency program. This initiative, co-organized by IBEC, the Centre de Cultura Contemporània de Barcelona (CCCB), IFAE, ICFO, and ALBA Synchrotron, aims to foster interdisciplinary collaboration between scientists and artists, exploring radical science through audiovisual works.

During their visit, Hamill Industries explored several cutting-edge research laboratories, including MicroFab & Microscopy Unit (Unit 7 of NANBIOSIS) located at IBEC. They engaged with state-of-the-art nanofabrication and bionanocharacterization technologies available at the Microfabspace and the Microscopy Characterization Facilities within Core Facilities of IBEC. This interaction allowed them to gain valuable insights into the intricate world of nanoscience and nanotechnology, inspiring their creative process.

About NANBIOSIS Unit 7: MicroFab & Microscopy Platform

Unit 7, hosted at IBEC, is a key research Unit dedicated to the fabrication and characterization of micro and nanodevices. Under the leadership of Prof. Josep Samitier (Scientific Director), Dr. Isabel Oliveira (Technical Coordinator), and Dr. Teresa Galán (Scientific Coordinator), this platform provides access to a 150m² class 10,000 cleanroom space and state-of-the-art laboratory equipment.

This cutting-edge facility supports academic and industrial researchers in areas such as nanobioengineering, BioMEMS, materials science, tissue engineering, optics, and biomaterials. Services include the design, development, and analysis of microfluidic devices, nanostructured surfaces, and other advanced technological applications, making it a crucial hub for scientific innovation in Catalonia.

Bridging Art and Science

At IBEC, transdisciplinary research is a core principle. The collaboration with Hamill Industries exemplifies how artistic perspectives can enrich the dissemination of scientific knowledge. By integrating art with nanotechnology, the Ciència Radical program not only pushes creative boundaries but also brings complex scientific concepts to a broader audience.

High-resolution 3D bioprinter at the facilities of NANBIOSIS Unit 7 at IBEC.

Get Involved

The artistic residency program at IBEC remains open on a rolling basis. Artists interested in exploring new dimensions of their practice through collaboration with leading scientific institutions are encouraged to apply.

Stay tuned for the upcoming audiovisual work by Hamill Industries, which promises to offer a unique artistic interpretation of the groundbreaking research conducted at IBEC and NANBIOSIS Unit 7!

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS and IBIMA: new bioimaging techniques in cutting-edge research

NANBIOSIS presented its capacities at IBIMA, showcasing services, success stories, and exploring collaborations to advance biomedical research.

Málaga, march 2025. On March 11, 2025, Elisa Checa, Coordinator of NANBIOSIS-ICTS, delivered a presentation titled “NANBIOSIS: Capacities and Success Stories” at the IBIMA BIONAND Platform Assembly Hall. The event, attended by researchers from IBIMA, highlighted the wide range of services and infrastructures offered by NANBIOSIS to support biomedical and nanotechnology research.

As one of the three nodes that form NANBIOSIS, IBIMA plays a crucial role in advancing scientific innovation. During the visit, the NANBIOSIS coordination team toured the IBIMA facilities, gaining a deeper insight into the cutting-edge technologies available at the institute. The visit also included a strategic meeting with the IBIMA directives to explore future collaborations and synergies between the institutions.

Elisa Checa, coordinator of NANBIOSIS, previous to her presentation at IBIMA

The presentation provided a comprehensive overview of the capabilities of NANBIOSIS, emphasizing its role in facilitating translational research through state-of-the-art infrastructure and services. Attendees learned about success stories in research and technological development enabled by NANBIOSIS, reinforcing its importance as a key resource for scientists and innovators.

Elisa Checa, coordinator of NANBIOSIS, explaining the capabilities of the network at IBIMA

NANBIOSIS Unit 28: A key pillar in bioimaging

IBIMA hosts the NanoImaging Unit (U28) of NANBIOSIS, located at the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND). This Unit is designed to provide integrated technological support for biomedical research, offering advanced imaging services to internal and external users. Under the coordination of Dr. Mª Luisa García Martín, the Unit specializes in:

  • Small Animal Multimodal Imaging, featuring MRI, in vivo bioluminescence and fluorescence imaging, and micro-CT for preclinical studies.
  • Magnetic Resonance (NMR), with high-resolution spectrometers for routine and advanced studies.
  • Electron Microscopy, providing access to high-resolution TEM, Cryo-TEM, SEM, and Electron Tomography for nano- and micro-scale structural characterization.
  • Advanced Fluorescence, supporting biomedical research with applications ranging from fluorescence characterization of nano-compounds to preclinical evaluations.

Additionally, IBIMA’s NanoImaging Unit (Unit 28) is also linked to other complementary services, such as cell culture, animal house, and histology, offering researchers a comprehensive platform for multidisciplinary studies.

TEM system with capability for cryo-TEM and electron tomography, part of the services of Unit 28.

NANBIOSIS extends its gratitude to all participants and IBIMA for hosting this event. The collaboration between NANBIOSIS and IBIMA reinforces their shared mission of advancing research in nanomedicine and biotechnology. We look forward to fostering further partnerships and continuing to support the scientific community with cutting-edge research infrastructures.

IBIMA and NANBIOSIS team. Left to right: Javier Márquez (Scientific Vice-director of IBIMA plataforma Bionand), Marga Casado (Manager of NANBIOSIS), Ramón Martínez-Máñez (Scientific Director of NANBIOSIS), Elisa Checa (Coordinator of NANBIOSIS), Francisco Tinahones (Scientific Director of IBIMA plataforma Bionand), Mª Luisa García (Scientific Director of Unit 28 at IBIMA), Mónica Feijóo Cuaresma (Scientific Coordinator of Unit 28 at IBIMA), José Miguel Guzmán (Managing Director of FIMABIS).

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More